肿瘤组织乏氧与葡萄糖代谢

司宏伟; 徐慧琴; 岳峤; 耿建华; 陈盛祖

doi:10.3760/cma.j.issn.1673-4114.2009.04.003

肿瘤组织乏氧与葡萄糖代谢

司宏伟 , 徐慧琴 , 岳峤 , 耿建华 , 陈盛祖

文章导航 > 国际放射医学核医学杂志 > 2009, 33 > 4: (200-203)

引用本文:

Citation:

肿瘤组织乏氧与葡萄糖代谢

1. 安徽医科大学第一附属医院核医学科, 合肥, 230022;
2. 中国医学科学院北京协和医学院肿瘤医院核医学科, 北京, 100021

通讯作者: 司宏伟, sihw@163.com ;

基金项目:
安徽省自然科学基金(项目编号:090413132)

Hypoxia and glycometabolism in cancer tissue

l. Department of Nuclear Medicine, the First Affiliated Hospital of Anhui Medical University, Hefei 230022, China;
2. Department of Nuclear Medicine, Chinese Academy of Medical Sciences and Peking Union Medical College Cancer Hospital, Beijing 100021, China

Corresponding author: SI Hong-wei, sihw@163.com ;

摘要: 乏氧是导致放、化疗失败原因之一,活体探知葡萄糖和乏氧代谢空间分布,有助于修订放疗计划以提高治疗效果、早期评估患者放化疗疗效和预后。¹⁸F-氟脱氧葡萄糖(¹⁸F-FDG)沉积主要依赖血流供应,与细胞摄取率关系较弱,且仅反映肿瘤细胞膜葡萄糖通量大小,无法区分有氧代谢、细胞增殖旺盛组织和乏氧组织。临床经验提示,¹⁸F-FDG综合反映肿瘤恶性程度,且葡萄糖代谢和乏氧代谢空间分布差异大者肿瘤侵袭性较强。¹⁸F-FDG和¹⁸F-氟米索硝唑的摄取总体相仿,但不能除外局部差异。目前的研究结果并不能完全否认¹⁸F-FDG可作为乏氧标志物使用,但其评估肿瘤乏氧状态的价值或特异性有限。
- 肿瘤 /
- 细胞低氧 /
- 米索硝唑 /
- 氟脱氧葡萄糖F18
Abstract: The resistant of hypoxia tumor cell to radiotherapy and chemotherapy is one of the reasons that lead to therapy failure. To detect the distribution difference of hypoxia and glycometabolism in vivo is helpful to revise radiotherapy plan in order to improve the therapeutic effect, or to evaluate the prognosis shortly after radiotherapy and chemotherapy. TTie deposition of ¹⁸F-fluorodeoxyglucose (¹⁸F-FDG) mainly depends on blood flow with weak relation to uptake rate, and only reflects the membrane flux of glucose without distinguishing aerobic metabolism, enhanced cell proliferation and hypoxia tissue. Clinical experience indicated that ¹⁸F-FDG could integratedly reflect the malignant degree of tumor for the more difference between the distribution of hypoxia and glycometabolism, the more invasion of the tumor. The distribution of ¹⁸F-FDG and ¹⁸F-fluoromisonidazole were similar in general, but can not exclude minor deference. Current studies can not deny ¹⁸F-FDG as a hypoxia agent with a limited value and specificity.
- Neoplasms /
- Ceil hypoxia /
- Misonidarole /
- Fluorodeoxyglucose F18
本作品遵循Signature-Non-Commercial Use 4.0 International (CC BY-NC 4.0)协议

[1]	Thomlinson RH,Gray LH,The histological structure of some human lung cancers and the possible implications for radiotherapy.Br J Cancer,1955, 9(4):539-549.
[2]	Fyles AW,Milosevic M,Wong et al.Oxygenation predicts radiation response and survival in patients with cervix cancer.Radiother Oncol,1998,48(2):149-156.
[3]	Busk M,Horsman MR,Kristjansen PE,et al.Aerobic glycolysis in cancers:implications for the usability of oxygen-responsive genes and fluorodeoxyglucose-PET as markers of tissue hypoxia.Int J Cancer,2008,122(12):2726-2734.
[4]	Dierckx RA,Van de Wiele C.FDG uptake,a surrogate of tumour hypoxia?.Eur J Nucl Med Mol Imaging,2008,35(8):1544-1549.
[5]	Wei W,Yu XD,Hypoxia-inducible factors:crosstalk between their protein stability and protein degradation.Cancer Lett,2007,257(2):145-156.
[6]	Maloyan A,Eli-Berchoer L,Semenza GL,et al.HIF-lalpha-targeted pathways are activated by heat acclimation and contribute to acclimation-ischemic cross-tolerance in the heart.Physiol Genomics,2005,23(1):79-88
[7]	Airley RE,Mobasheri A.Hypoxic regulation of glucose transport,anaerobic metabolism and angiogenesis in cancer novel pathways and targets for anticancer therapeutics.Chemotherapy,2007,53(4):233-256.
[8]	Clavo AC,Brown RS,Wahl RL.Fluorodeoxyglucose uptake in human cancer cell lines is increased by hypoxia.J Nucl Med,1995,36(9):1625-1632.
[9]	Thorwarth D, Eschmann SM, Holzner F,et al Combined uptake of[¹⁸F] FDC and[¹⁸F] FMISO correlates with radiation therapy outcome in head-and-neck cancer patients.Radiother Oncol,2006,80(2):151-156.
[10]	Schroeder T,Yuan H,Viglianti BL,et al.Spatial heterogeneity and oxygen dependence of glucose consumption in R3230Ac and fibrosarcomas of the Fischer 344 rat.Cancer Res,2005,65(12):5163-5171.
[11]	Troost EG,Laverman P, Kaanders JH,et al.Imaging hypoxia after oxygenation-modificalion:comparing[¹⁸F] FMIS0 autoradiography with pimonidazole immunohistochemistry in human xenograft tumors.Radiother Oncol,2006,80(2):157-164.
[12]	Pugachev A,Ruan S,Carlin S,et al.Dependence of FDG uptake on tumor microenvironment.Int J Radiat Oncol Biol Phys,2005,62(2):545-553.
[13]	Tanaka T,Furukawa T,Fujieda S,et al.Double-tracer autoradiography with Cu-ATSM/FDG and immunohistochemical interpretation in four different mouse implanted tumor models,Nucl Med Biol,2006,33(6):743-750.
[14]	Picchio M,Beck R,Haubner R,et al.Intratumoral spatial distribution of hypoxia and angiogenesis assessed by ¹⁸FAZA and ¹²⁵I-Gluco-RGD autoradiography.J Nucl Med,2008,49(4):597-605.
[15]	Zanzonico P,O'Donoghue J,Chapman JD,et al.Iodine-124-labeled iodo-azomycin-galactoside imaging of tumor hypoxia in mice with serial microPET scanning-Eur J Nucl Med Mol Imaging,2004,31(1):117-128.
[16]	Dence CS,Ponde DE, Welch MJ,et al.Autoradiographic and small-animal PET comparisons between ¹⁸F-FMISO,¹⁸F-FDG,¹⁸F-FLT and the hypoxic selective ⁶⁶Cu-ATSM in a rodent model ofcancer.Nucl Med Biol,2008, 35(6):713-720.
[17]	Obata A,Yoshimoto M,Kasamatsu S,et al.Intra-tiunoral distribution of ⁶⁶Cu-ATSM:a comparison study with FDG.Nucl Med Biol,2003,30(5):529-534.
[18]	Wyss MT,Honer M,Schubiger PA,et al.NanoPET imaging of[¹⁸F] fluoromisonidazole uptake in experimental mouse tumours.Eur J Nucl Med Mol Imaging 2006,33(3):311-318.
[19]	Zanzonico P,Carapa J,Polycarpe-Holman D,et al.Animal-specific positioning molds for registration of repeat imaging studies:comparative microPET imaging of F18-labeled fluoro-deoxyglucose and fluoro-misonidazole in rodent tumors.Nucl Med Biol,2006,33(1):65-70.

[1]	孙琳 , 高再荣 , 张永学 . ¹⁸F-氟代脱氧葡萄糖PET-CT用于恶性肿瘤治疗疗效评估与监测. 国际放射医学核医学杂志, 2006, 30(6): 328-331.
[2]	吕慧清 , 张中民 , 吕仲虹 . ¹⁸F-氟代脱氧葡萄糖PET在恶性肿瘤适形放射治疗中的价值. 国际放射医学核医学杂志, 2006, 30(6): 335-337.
[3]	宋少莉 , 黄钢 . ¹⁸F-氟脱氧葡萄糖PET监测实体瘤放化疗疗效的应用进展. 国际放射医学核医学杂志, 2007, 31(5): 284-288.
[4]	邢岩 , 赵晋华 . ¹⁸F-氟脱氧葡萄糖PET及PET-CT早期诊断肿瘤复发. 国际放射医学核医学杂志, 2007, 31(6): 341-344.
[5]	郑磊 , 李前伟 . ¹⁸F-氟脱氧葡萄糖PET在原发陛肝细胞癌中的应用. 国际放射医学核医学杂志, 2008, 32(1): 23-26.
[6]	张玉娜 , 赵晋华 . ¹⁸F-氟脱氧葡萄糖PET-CT在头颈部肿瘤临床诊治中的价值. 国际放射医学核医学杂志, 2007, 31(6): 359-362.
[7]	曹霞 , 谢爱民 , 莫逸 , 彭翔 . ¹⁸F-氟脱氧葡萄糖PET-CT在非小细胞肺癌临床分期及经治患者疗效评价中的应用. 国际放射医学核医学杂志, 2008, 32(4): 214-216.
[8]	叶慧 , 莫逸 , 谢爱民 , 彭翔 . ¹⁸F-氟脱氧葡萄糖PET-CT与99nTc-亚甲基二膦酸盐骨显像诊断转移性骨肿瘤的对比研究. 国际放射医学核医学杂志, 2008, 32(3): 147-150.
[9]	郭阳 . 红细胞生成素及其受体与肿瘤组织乏氧的关系及对治疗的影响. 国际放射医学核医学杂志, 2007, 31(5): 306-308.
[10]	江茂情 , 吴华 . ¹⁸F-FDG和¹⁸F-FLT PET对肿瘤放化疗疗效评价的实验研究. 国际放射医学核医学杂志, 2011, 35(3): 146-151. doi: 10.3760/cma.j.issn.1673-4114.2011.03.004

点击查看大图

计量

文章访问数: 2016
HTML全文浏览量: 377
PDF下载量: 4

肿瘤组织乏氧与葡萄糖代谢

通讯作者: 司宏伟, sihw@163.com;

1. 安徽医科大学第一附属医院核医学科, 合肥, 230022;
2. 中国医学科学院北京协和医学院肿瘤医院核医学科, 北京, 100021

收稿日期: 2009-04-07

基金项目: 安徽省自然科学基金(项目编号:090413132)

关键词:

摘要: 乏氧是导致放、化疗失败原因之一,活体探知葡萄糖和乏氧代谢空间分布,有助于修订放疗计划以提高治疗效果、早期评估患者放化疗疗效和预后。¹⁸F-氟脱氧葡萄糖(¹⁸F-FDG)沉积主要依赖血流供应,与细胞摄取率关系较弱,且仅反映肿瘤细胞膜葡萄糖通量大小,无法区分有氧代谢、细胞增殖旺盛组织和乏氧组织。临床经验提示,¹⁸F-FDG综合反映肿瘤恶性程度,且葡萄糖代谢和乏氧代谢空间分布差异大者肿瘤侵袭性较强。¹⁸F-FDG和¹⁸F-氟米索硝唑的摄取总体相仿,但不能除外局部差异。目前的研究结果并不能完全否认¹⁸F-FDG可作为乏氧标志物使用,但其评估肿瘤乏氧状态的价值或特异性有限。